Human safety trials of a novel antibiotic treatment for Lyme disease developed by Northeastern professor Kim Lewis are scheduled to start this spring in Australia, with results anticipated by fall.
“Hopefully, the results will be positive,” says Lewis, University Distinguished Professor of Biology.
So far the therapeutic agent, an antibiotic known as hygromycin A, has not been toxic in animals and has cleared Lyme in mice, he says.
Read more from Northeastern Global News
Photo by Julian Stratenschulte/picture-alliance/dpa/AP Images
